Creative Biogene Unveils Lung Cancer Pathway Related Products to Accelerate The Drug Discovery Projects

Creative Biogene, the world’s leading biotechnology products and services provider, today announced the launch of its flagship offering lung cancer pathway products.

New York, Jul 19th, 2019 – Creative Biogene, the world’s leading biotechnology products and services provider, today announced the launch of its flagship offering lung cancer pathway products which can help researchers to develop the further study of drug discovery and accelerate the process, aiming to provide powerful support for the therapeutic strategies.


Currently, lung cancer has become the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC), which is any type of epithelial lung cancer other than small cell lung cancer (SCLC). In the past two decades, several anti-angiogenic and epidermal growth factor (EGF) pathway chemotherapeutics and molecular targeting drivers have been successfully tested in NSCLC. Researchers have spent years of efforts trying to discover effective methods for lung cancer treatment, in which, NSCLC molecular profiling has been proved to be an important factor in therapeutic decision making, with many emerging oncogenic targets and active targeted drugs.


Creative Biogene is capable to offer various gene that can be effective in lung cancer pathway related research, ALK and KRAS are included. Depending on the cancer research data shows, ALK positive patients take accounts for 3% to 5% in Non-small cell lung cancer. In recent years, many small molecule ALK inhibitors have been developed for the treatment of ALK positive NSCLC. The first-generation ALK inhibitor crizotinib has a significant effect on ALK-positive NSCLC patients and has become the first-line treatment for ALK-positive NSCLC treatment, but the emergence of drug resistance limits its clinical application. The ALK gene offered by Creative Biogene can help promote more new ALK inhibitors with better safety, higher selectivity or better activity which can be applied in lung cancer treatment.


Besides, pathological studies have shown that Kras mutations are more common in patients with lung adenocarcinoma, KRAS is also considered a marker of prognosis in patients with lung cancer. In patients with non-small cell lung cancer, patients with KRAS mutations have shorter survival than patients with wild-type Kras, especially those with G12C mutations.


‘Since the protein product of the KRAS gene plays an important role in normal tissue signaling, and mutation of the KRAS gene is an essential step in the development of many cancers, it has become vital in cancer related research.’ said Marcia Brady, the marketing director of Creative Bigoene, she also claimed that, ‘Except for what being mentioned here, we also insist offering the comprehensive support for various genes that can be utilized in cancer related research so that promote the development for new clinical methods and drug discovery.’


About Creative Biogene

Creative Biogene, as a top-of-its-kind company who holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 6316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States